Gary B. Gordon, M.D., PhD
Vice President, Global Oncology Development, AbbVie, Inc.
In Dr. Gordon current role, he oversees development of AbbVie’s oncology projects. He joined AbbVie in April 2003 and assumed his current role in July 2004. Prior to joining AbbVie, Dr. Gordon was chief scientific officer and vice president of clinical affairs at Ovation Pharmaceuticals from 2001 to 2003. In this role, he helped obtain funding and introduce five therapies to the market.
He entered the pharmaceutical industry in 1995 when he joined the G.D. Searle division of Monsanto, which eventually became part of Pharmacia. Dr. Gordon’s responsibilities included programs related to COX-2 inhibitors for the prevention and treatment of cancer, the development of angiogenesis inhibitors, and involvement in the hematopoietic and cancer immunization programs. He also helped establish a tissue bank project and a discovery-clinical interface program.
Dr. Gordon is certified in internal medicine and medical oncology through the American Board of Internal Medicine. His professional memberships include the American Association for Cancer Research and the American Society of Clinical Oncology. Dr. Gordon began his career at the Johns Hopkins University (JHU) School of Medicine as a medical student and also worked as an associate professor of medical oncology.
Dr. Gordon received a BS degree in biochemistry from the State University of New York at Stony Brook, and his MD and PhD degrees in pharmacology and experimental therapeutics from JHU.